Injectable doxorubicin-loaded hyaluronic acid-based hydrogel for locoregional therapy and inhibiting metastasis of breast cancer

作者：Yongli Shi, Huiqing Zhu, Suyue Xu, Jingya Zhao, Yuxin Wang, Xiaofei Pan, Bingqian Zhao, Zeyu Sun, Yilin Yin, Lei Xu, Fengjiao Wei, Sisi He, Xueyan Hou, Jintao Xue · 发表于：Colloids and Surfaces B Biointerfaces · 年份：2024 · DOI：10.1016/j.colsurfb.2024.114433 · 被引用次数：15 · 研究领域：Proteoglycans and glycosaminoglycans research、Fibroblast Growth Factor Research、Mesenchymal stem cell research

Therapy and metastasis pose significant challenges for breast cancer therapy. Locoregional chemotherapy presents a promising strategy to address these dilemmas. In this study, a doxorubicin-loaded injectable hydrogel based on hyaluronic acid (DOX-MCHA gel ) was fabricated for locoregional chemotherapy and inhibiting the metastasis of breast cancer. The high bio-safety of cargo-free hydrogels (MCHA gel ) would enhance patient compliance. The sustained DOX release behaviors from DOX-MCHA gel (over 10 days) could reduce dosing frequency and achieve long-term therapeutic effects. The potent in vivo anti-tumor activity of DOX-MCHA gel was verified by the smallest tumor volumes, the largest number of apoptotic cells, and the strongest fluorescence intensity in TUNEL sections. Notably, the injectable DOX-MCHA gel not only greatly suppressed the growth of 4T1 tumor tissues, but also effectively curbed the liver and lung metastasis in vivo . Moreover, the survival of 4T1-tumor bearing mice was extended without obvious systemic toxicity. In brief, the novel injectable hydrogel developed in this study offers a new strategy for locoregional therapy and inhibiting metastasis of breast cancer.